Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
69.24 x 1 69.55 x 1
Post-market by (Cboe BZX)
69.30 -0.86 (-1.23%) 03/28/25 [NYSE]
69.24 x 1 69.55 x 1
Post-market 69.30 unch (unch) 19:54 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
69.18
Day High
70.35
Open 70.17
Previous Close 70.16 70.16
Volume 5,867,000 5,867,000
Avg Vol 7,093,965 7,093,965
Stochastic %K 1.57% 1.57%
Weighted Alpha -52.10 -52.10
5-Day Change -7.56 (-9.84%) -7.56 (-9.84%)
52-Week Range 69.18 - 148.15 69.18 - 148.15
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 310,985,984
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 18,609 M
  • EBITDA $ 21,380 M
  • 60-Month Beta 0.42
  • Price/Sales 7.47
  • Price/Cash Flow 18.08
  • Price/Book 15.13

Options Overview Details

View History
  • Implied Volatility 46.87% ( +4.09%)
  • Historical Volatility 47.81%
  • IV Percentile 90%
  • IV Rank 66.19%
  • IV High 58.88% on 12/19/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 1.58
  • Today's Volume 33,105
  • Volume Avg (30-Day) 33,600
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 490,616
  • Open Int (30-Day) 418,028

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.93
  • Number of Estimates 4
  • High Estimate 1.00
  • Low Estimate 0.84
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +12.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.18 +0.17%
on 03/28/25
Period Open: 90.65
91.90 -24.59%
on 03/05/25
-21.35 (-23.55%)
since 02/28/25
3-Month
69.18 +0.17%
on 03/28/25
Period Open: 87.37
93.80 -26.12%
on 02/25/25
-18.07 (-20.68%)
since 12/27/24
52-Week
69.18 +0.17%
on 03/28/25
Period Open: 128.40
148.15 -53.22%
on 06/25/24
-59.10 (-46.03%)
since 03/28/24

Most Recent Stories

More News
Is Hims & Hers Stock Too Cheap to Pass Up?

This high-growth stock may be cheaper than you think.

NVDA : 109.67 (-1.58%)
HIMS : 29.14 (-8.71%)
NVO : 69.30 (-1.23%)
JNJ : 163.71 (+0.36%)
LLY : 822.51 (+0.10%)
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian

Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates...

NVO : 69.30 (-1.23%)
AVDE : 66.90 (-0.79%)
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand.

HIMS : 29.14 (-8.71%)
NVO : 69.30 (-1.23%)
Why Novo Nordisk Stock Dipped on Thursday

Novo Nordisk 's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like the company ingested some of its own treatment. Its U.S.-traded American...

NVO : 69.30 (-1.23%)
MS : 115.33 (-3.08%)
LLY : 822.51 (+0.10%)
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
EXEL : 36.70 (-0.38%)
BMY : 60.02 (+1.90%)
1 Growth Stock Down 40% to Buy and Hold Forever

This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-month...

NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule Lipoprotein(a)...

AZN : 73.79 (+1.30%)
NVO : 69.30 (-1.23%)
MRK : 89.23 (+1.86%)
Is Novo Nordisk Stock a Buy?

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

NVO : 69.30 (-1.23%)
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation

Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
GILD : 111.79 (+0.57%)
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
GILD : 111.79 (+0.57%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
NVS : 112.57 (+1.05%)
ABBV : 205.29 (+1.27%)
PFE : 25.21 (+0.80%)
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves

Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland China,...

APIE : 30.25 (-1.08%)
NVO : 69.30 (-1.23%)
AVDE : 66.90 (-0.79%)
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped

There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.

NVO : 69.30 (-1.23%)
HIMS : 29.14 (-8.71%)
LLY : 822.51 (+0.10%)
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame,...

NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
RHHBY : 41.9200 (-1.02%)
AMGN : 306.95 (+0.39%)
Motley Fool 2025 March Market Cap Showdown Championship

It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending Champion Andy Cross has held off all contenders and pretenders, but game show...

TWLO : 98.98 (-2.79%)
AMAT : 145.06 (-1.77%)
APP : 272.38 (+4.08%)
AAPL : 217.90 (-2.66%)
NDAQ : 74.91 (-1.90%)
HLF : 8.57 (-0.58%)
BRZE : 37.51 (+2.21%)
KMI : 28.37 (+0.50%)
NVO : 69.30 (-1.23%)
PTON : 6.30 (-6.94%)
WIX : 166.36 (-4.32%)
BRK.TO : 39.47 (-1.57%)
This Vanguard ETF Is Crushing the Market in 2025. Should You Buy?

President Donald Trump has been in office for only two months, but already his saber-rattling over tariffs has roiled markets.

VEA : 51.24 (-1.14%)
SAP : 268.00 (-0.06%)
NVO : 69.30 (-1.23%)
$SPX : 5,580.94 (-1.97%)
TM : 179.07 (-2.67%)
HSBC : 57.77 (-0.98%)
NSRGY : 102.3400 (+0.52%)
ASML : 674.58 (-2.32%)
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
ABBV : 205.29 (+1.27%)
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according...

VKTX : 25.65 (-1.84%)
NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has...

NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
HLN : 10.24 (+1.19%)
GSK : 38.74 (+0.57%)
Is This Simple Index Fund a Millionaire Maker?

Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few opportunities and several challenges.

MSFT : 378.80 (-3.02%)
NVDA : 109.67 (-1.58%)
AAPL : 217.90 (-2.66%)
VEA : 51.24 (-1.14%)
SAP : 268.00 (-0.06%)
NVO : 69.30 (-1.23%)
$SPX : 5,580.94 (-1.97%)
VOO : 510.80 (-2.00%)
ASML : 674.58 (-2.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 71.21
2nd Resistance Point 70.78
1st Resistance Point 70.04
Last Price 69.30
1st Support Level 68.87
2nd Support Level 68.44
3rd Support Level 67.70

See More

52-Week High 148.15
Fibonacci 61.8% 117.98
Fibonacci 50% 108.66
Fibonacci 38.2% 99.35
Last Price 69.30
52-Week Low 69.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.